Clinical Trial Update: Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 trial assessing rapamycin's effect on the mTOR pathway in mild cognitive impairment and Alzheimer's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Cognitive Impairment, Mild, Alzheimer Disease | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2023-03-21